Antikörpertestung in der Nierentransplantation

ZUSAMMENFASSUNG

Das HLA-System (HLA: humane Leukozytenantigene) spielt eine wichtige Rolle bei der Transplantation (Tx) der Niere. Daher ist der Nachweis von HLA-Antikörpern vor und nach der Tx entscheidend für die Betreuung des Patienten, wobei verschiedene Verfahren eingesetzt werden. Der Nachweis von donorspezifischen HLA-Antikörpern (DSA) ist gemäß Banff-Klassifikation [1] ein wichtiges Kriterium für die Diagnostik der antikörpervermittelten Abstoßung (ABMR: „antibody-mediated rejection“). Die Untersuchung auf präformierte sowie auf de novo DSA zu verschiedenen Zeitpunkten nach der Tx kann helfen, das individuelle Risiko für eine ABMR zu beurteilen.

• Literatur

• 1 Roufosse C, Simmonds N, Clahsen-van Groningen M. et al A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation 2018; 102: 1795-1814
• 2 Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813-1821
• 3 Halloran PF, Reeve JP, Pereira AB. et al Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int 2014; 85: 258-264
• 4 Sellares J, de Freitas DG, Mengel M. et al Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399
• 5 Zhang R. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol 2018; 13: 182-192
• 6 Haarberg KM, Tambur AR. Detection of donor-specific antibodies in kidney transplantation. Br Med Bull 2014; 110: 23-34
• 7 Institut für Immunologie, Universität Heidelberg. Collaborative Transplant Study. Im Internet. https://www.ctstransplant.org/public/graphics/sample.shtml Stand: 15.06.2023
• 8 Lefaucheur C, Louis K, Morris AB. et al Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document. Am J Transplant 2023; 23: 115-132
• 9 Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739
• 10 Lachmann N, Todorova K, Schulze H. et al Luminex(^®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion. Transfus Med Hemother 2013; 40: 182-189
• 11 Gebel HM, Bray RA. HLA antibody detection with solid phase assays: great expectations or expectations too great?. Am J Transplant 2014; 14: 1964-1975
• 12 In JW, Rho EY, Shin S. et al False-positive reactions against HLA class II molecules detected in Luminex single-antigen bead assays. Ann Lab Med 2014; 34: 408-410
• 13 Dean CL, Krummey SM, Gebel HM. et al Identification of a recurrent pattern of false-positivity by Luminex HLA MHC class I single antigen bead testing. Hum Immunol 2020; 81: 73-78
• 14 Schnaidt M, Weinstock C, Jurisic M. et al HLA antibody specification using single-antigen beads--a technical solution for the prozone effect. Transplantation 2011; 92: 510-515
• 15 Tambur AR, Wiebe C. HLA Diagnostics: Evaluating DSA strength by titration. Transplantation 2018; 102: S23-S30
• 16 Gu Y, Koh RWK, Lai ML. et al Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation. Sci Rep 2020; 10: 18397
• 17 Tambur AR, Schinstock C. Clinical utility of serial serum dilutions for HLA antibody interpretation. HLA 2022; 100: 457-468
• 18 Lobashevsky AL. Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation. World J Transplant 2014; 04: 153-167
• 19 Wiebe C, Gibson IW, Blydt-Hansen TD. et al Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015; 15: 2921-2930
• 20 Bharadwaj P, Shrestha S, Pongracz T. et al Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation. Cell Rep Med 2022; 03: 100818
• 21 de Castro MCR, Barbosa EA, Souza RP. et al The kinetics of anti-HLA antibodies in the first year after kidney transplantation: In whom and when should they be monitored?. J Transplant 2018; 2018: 8316860
• 22 Tambur AR, Herrera ND, Haarberg KM. et al Assessing antibody strength: comparison of MFI, C1q, and titer information. Am J Transplant 2015; 15: 2421-2430
• 23 Loupy A, Lefaucheur C, Vernerey D. et al Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226
• 24 Tatapudi VS, Kopchaliiska D, da Gente GJ. et al Solid-phase C1q/C3d fixing readouts correlate with high median fluorescence intensity (MFI) de novo donor-specific HLA antibodies and C4d(+) antibody-mediated rejection in kidney transplant recipients. Ann Transplant 2021; 26: e934175
• 25 Lefaucheur C, Viglietti D, Bentlejewski C. et al IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 2016; 27: 293-304
• 26 Viglietti D, Loupy A, Vernerey D. et al Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol 2017; 28: 702-715
• 27 Arbeitsgemeinschaft der Nierentransplantationszentren Nordrhein-Westfalens. Manual zur Vereinheitlichung der Evaluation vor Nierentransplantation und Nierenlebendspende, der Wartelistenführung vor Nierentransplantation und zur Nachsorge nach Nierentransplantation und Nierenlebendspende. Konsensus der Arbeitsgemeinschaft der Nierentransplantationszentren Nordrhein-Westfalens (18.02.2021). Im Internet. https://www.dgfn.eu/tx-manual.html Stand: 15.06.2023
• 28 Tait BD, Susal C, Gebel HM. et al Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47
• 29 Kleid L, Walter J, Vorstandlechner M. et al Predictive value of molecular matching tools for the development of donor specific HLA-antibodies in patients undergoing lung transplantation. HLA 2023; 102: 331-342
• 30 Carapito R, Aouadi I, Verniquet M. et al The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation. Nat Med 2022; 28: 989-998
• 31 Kardol-Hoefnagel T, Otten HG. A Comprehensive overview of the clinical relevance and treatment options for antibody-mediated rejection associated with non-HLA antibodies. Transplantation 2021; 105: 1459-1470
• 32 Holt SG, Kotagiri P, Hogan C. et al The potential role of antibodies against minor blood group antigens in renal transplantation. Transpl Int 2020; 33: 841-848